NSEI:RPGLIFE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has RPG Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RPGLIFE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.3%

RPGLIFE

0.8%

IN Pharmaceuticals

2.9%

IN Market


1 Year Return

22.0%

RPGLIFE

28.1%

IN Pharmaceuticals

-4.9%

IN Market

Return vs Industry: RPGLIFE underperformed the Indian Pharmaceuticals industry which returned 28.1% over the past year.

Return vs Market: RPGLIFE exceeded the Indian Market which returned -4.9% over the past year.


Shareholder returns

RPGLIFEIndustryMarket
7 Day1.3%0.8%2.9%
30 Day-0.7%2.5%5.8%
90 Day13.8%11.3%18.5%
1 Year26.9%22.0%30.2%28.1%-3.0%-4.9%
3 Year-26.7%-30.1%6.9%3.8%1.5%-3.3%
5 Year40.8%32.0%-8.8%-12.1%26.8%17.0%

Price Volatility Vs. Market

How volatile is RPG Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is RPG Life Sciences undervalued compared to its fair value and its price relative to the market?

4.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RPGLIFE (₹270.4) is trading below our estimate of fair value (₹284)

Significantly Below Fair Value: RPGLIFE is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: RPGLIFE is good value based on its PE Ratio (15.4x) compared to the Pharmaceuticals industry average (17.8x).

PE vs Market: RPGLIFE is poor value based on its PE Ratio (15.4x) compared to the Indian market (12.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RPGLIFE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RPGLIFE is overvalued based on its PB Ratio (2.5x) compared to the IN Pharmaceuticals industry average (1.6x).


Next Steps

Future Growth

How is RPG Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has RPG Life Sciences performed over the past 5 years?

18.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RPGLIFE has high quality earnings.

Growing Profit Margin: RPGLIFE's current net profit margins (7.7%) are higher than last year (3.3%).


Past Earnings Growth Analysis

Earnings Trend: RPGLIFE's earnings have grown by 18.7% per year over the past 5 years.

Accelerating Growth: RPGLIFE's earnings growth over the past year (166.6%) exceeds its 5-year average (18.7% per year).

Earnings vs Industry: RPGLIFE earnings growth over the past year (166.6%) exceeded the Pharmaceuticals industry 18.6%.


Return on Equity

High ROE: RPGLIFE's Return on Equity (16.4%) is considered low.


Next Steps

Financial Health

How is RPG Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: RPGLIFE's short term assets (₹1.3B) exceed its short term liabilities (₹825.9M).

Long Term Liabilities: RPGLIFE's short term assets (₹1.3B) exceed its long term liabilities (₹75.7M).


Debt to Equity History and Analysis

Debt Level: RPGLIFE's debt to equity ratio (2.3%) is considered satisfactory.

Reducing Debt: RPGLIFE's debt to equity ratio has reduced from 26.4% to 2.3% over the past 5 years.

Debt Coverage: RPGLIFE's debt is well covered by operating cash flow (1251.1%).

Interest Coverage: RPGLIFE's interest payments on its debt are well covered by EBIT (24.5x coverage).


Balance Sheet


Next Steps

Dividend

What is RPG Life Sciences's current dividend yield, its reliability and sustainability?

1.48%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: RPGLIFE's dividend (1.48%) is higher than the bottom 25% of dividend payers in the Indian market (0.68%).

High Dividend: RPGLIFE's dividend (1.48%) is low compared to the top 25% of dividend payers in the Indian market (2.73%).


Stability and Growth of Payments

Stable Dividend: RPGLIFE's dividend payments have been volatile in the past 10 years.

Growing Dividend: RPGLIFE's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (13.7%), RPGLIFE's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Yugal Kishor Sikri (63yo)

1.75yrs

Tenure

₹22,075,328

Compensation

Mr. Yugal Kishor Choturam Sikri has been Managing Director and Additional Director at RPG Life Sciences Limited since October 1, 2018 .He served as an Independent & Non-Executive Director at RPG Life Scien ...


CEO Compensation Analysis

Compensation vs Market: Yugal Kishor's total compensation ($USD294.42K) is above average for companies of similar size in the Indian market ($USD49.46K).

Compensation vs Earnings: Yugal Kishor's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Yugal Kishor Sikri
MD & Additional Director1.75yrs₹22.08mno data
Mahesh Narayanaswamy
Vice President of Finance4yrsno datano data
Ramanathan Varadarajan
Chief Operating Officer0.33yrno datano data
Rajesh Shirambekar
Head of Legal8.67yrsno datano data
Tushar Joshi
Head of Human Resources3.83yrsno datano data
Suchitra Tiwari
Head of Regulatory & Project Managementno datano datano data
B. Sundaram
Business Head of API - International & Specialty4.83yrsno datano data
Himmat Patel
Head of Domestic Manufacturing & Sourcing3.25yrsno datano data
Kartick Patra
Head of API Operations & Procurement3.25yrsno datano data
Rajesh Chopra
Site Head - F2no datano datano data

3.5yrs

Average Tenure

Experienced Management: RPGLIFE's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yugal Kishor Sikri
MD & Additional Director1.75yrs₹22.08mno data
Lalit Kanodia
Independent & Non-Executive Director12.42yrs₹615.00kno data
Harsh Goenka
Chairman of the Boardno data₹600.00k0.16% 7.4m
Manojkumar Maheshwari
Independent & Non-Executive Director16yrs₹600.00kno data
Mahesh Gupta
Independent & Non-Executive Director16.75yrs₹704.00kno data
Narendra Ambwani
Independent & Non-Executive Director6yrs₹664.00k0.0060% 274.4k
Sachin Nandgaonkar
Non-Executive Director5.5yrs₹815.00kno data
Zahabiya Khorakiwala
Independent & Non-Executive Director4.75yrs₹410.00kno data
Bhaskar Iyer
Independent Non-Executive Directorno datano datano data

6.0yrs

Average Tenure

63yo

Average Age

Experienced Board: RPGLIFE's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

RPG Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RPG Life Sciences Limited
  • Ticker: RPGLIFE
  • Exchange: NSEI
  • Founded: 1968
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹4.535b
  • Shares outstanding: 16.54m
  • Website: https://www.rpglifesciences.com

Number of Employees


Location

  • RPG Life Sciences Limited
  • RPG HOUSE
  • 4th Floor
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532983BSE (Mumbai Stock Exchange)YesEquity SharesININRJun 2008
RPGLIFENSEI (National Stock Exchange of India)YesEquity SharesININRJun 2008

Biography

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company operates through Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients segments. It offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. The company also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as gastro-intestinal, pain management, cardio-vascular, and nephrology primarily under the Lomotil, Lomofen, Naprosyn, Azoran, Aldactone, and Serenace brands. In addition, it offers cosmetics, including evactive lubricating gel. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/09 12:54
End of Day Share Price2020/07/09 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.